B of A Securities Maintains Buy on Insmed, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Zemansky maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $35 to $37.
September 06, 2023 | 5:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities maintains a Buy rating on Insmed and raises the price target from $35 to $37.
The raised price target by B of A Securities indicates a positive outlook for Insmed. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100